Abstract

Summary Forty hyperkinetic children with patterns of organic brain damage were treated with a new type of “mental drug”, Suvren. Dosage varied from 100 to 250 mg. daily for periods of 3 to 17 months. Twenty-three patients showed striking improvement in action and behavior. No significant toxic reactions or untoward side effects were demonstrated. Our results indicate that Suvren isa safe and useful chemotherapeutic agent in the treatment of hyperactive children with brain damage.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call